EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

被引:3
|
作者
Le, Xiuning [1 ]
Nadler, Eric [2 ]
Costa, Daniel B. [3 ]
Heymach, John Victor [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA
关键词
AFATINIB; OSIMERTINIB; NSCLC;
D O I
10.1007/s11523-023-00994-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[media not available: see fulltext]
引用
收藏
页码:807 / 817
页数:11
相关论文
共 50 条
  • [41] Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
    Zhang, Tianli
    Wan, Bing
    Zhao, Yuan
    Li, Chuling
    Liu, Hongbing
    Lv, Tangfeng
    Zhan, Ping
    Song, Yong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 302 - 316
  • [42] Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
    Massarelli, Erminia
    Johnson, Faye M.
    Erickson, Heidi S.
    Wistuba, Ignacio I.
    Papadimitrakopoulou, Vassiliki
    LUNG CANCER, 2013, 80 (03) : 235 - 241
  • [43] Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan
    Chang, John Wen-Cheng
    Huang, Chen-Yang
    Fang, Yueh-Fu
    Chang, Ching-Fu
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Hsu, Ping-Chih
    Wu, Chiao-En
    THORACIC CANCER, 2023, 14 (01) : 12 - 23
  • [44] Postoperative management for non-small cell lung cancer harboring EGFR mutations
    Tanaka, Fumihiro
    Yoneda, Kazue
    Takenaka, Masaru
    JOURNAL OF THORACIC DISEASE, 2020, 12 (08) : 4556 - 4560
  • [45] Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer: A multi-centre retrospective analysis.
    Hunter, Sarah
    Nickless, Guillermina
    El-Shakankery, Karim
    Yousaf, Nadia
    Smith, Daniel
    Brand, Gillian
    Nicolson, Marianne
    Neat, Michael
    -Davies, Tom Newsom
    Spicer, James F.
    Montes, Ana
    Karapanagiotou, Eleni
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an EGFR::ERBB4 Fusion Through Use of EGFR Tyrosine Kinase Inhibitors
    Guimaraes-Young, Amy
    Davies, Kurtis D.
    Trevisan, Patricia
    Nijmeh, Hala
    Haag, Mary
    Aisner, Dara L.
    Patil, Tejas
    JCO PRECISION ONCOLOGY, 2024, 8
  • [47] The Glasgow prognostic score predicts survival in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations who are treated with EGFR tyrosine kinase inhibitors
    Akazawa, Yuki
    Igawa, Satoshi
    Yamada, Kaori
    Yamamoto, Hiroki
    Yagami, Yuri
    Kaizuka, Nobuki
    Manaka, Hiroya
    Kasajima, Masashi
    Nakahara, Yoshiro
    Sato, Takashi
    Mitsufuji, Hisashi
    Yokoba, Masanori
    Kubota, Masaru
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    ONCOLOGY, 2023, 101 (11) : 685 - 694
  • [48] Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
    Wang, Mengzhao
    Xu, Yan
    Huang, Wen-Tsung
    Su, Wu-Chou
    Gao, Bo
    Lee, Chee Khoon
    Fang, Jian
    Zhu, Xuehua
    Yang, Zhenfan
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    LUNG CANCER, 2025, 199
  • [49] Current management of uncommon EGFR mutations in non-small cell lung cancer
    Trinh, Jonathan Q.
    Abughanimeh, Omar
    CURRENT PROBLEMS IN CANCER, 2024, 49
  • [50] Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
    Zhao, Yiming
    Wang, Shuyuan
    Zhang, Bo
    Qiao, Rong
    Xu, Jianlin
    Zhang, Lele
    Zhang, Yanwei
    Han, Baohui
    TARGETED ONCOLOGY, 2019, 14 (02) : 169 - 178